Boston Scientific (NYSE:BSX) and SANUWAVE Health (OTCMKTS:SNWV) are both medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their valuation, risk, institutional ownership, dividends, earnings, analyst recommendations and profitability.
This is a breakdown of recent recommendations and price targets for Boston Scientific and SANUWAVE Health, as provided by MarketBeat.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
Boston Scientific presently has a consensus price target of $44.01, suggesting a potential upside of 4.17%. Given Boston Scientific’s higher probable upside, equities research analysts plainly believe Boston Scientific is more favorable than SANUWAVE Health.
This table compares Boston Scientific and SANUWAVE Health’s net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
Earnings and Valuation
This table compares Boston Scientific and SANUWAVE Health’s gross revenue, earnings per share and valuation.
|Gross Revenue||Price/Sales Ratio||Net Income||Earnings Per Share||Price/Earnings Ratio|
|Boston Scientific||$9.82 billion||5.98||$1.67 billion||$1.47||28.74|
|SANUWAVE Health||$1.85 million||13.26||-$11.63 million||($0.08)||-1.63|
Boston Scientific has higher revenue and earnings than SANUWAVE Health. SANUWAVE Health is trading at a lower price-to-earnings ratio than Boston Scientific, indicating that it is currently the more affordable of the two stocks.
Volatility & Risk
Boston Scientific has a beta of 0.8, indicating that its share price is 20% less volatile than the S&P 500. Comparatively, SANUWAVE Health has a beta of -1.46, indicating that its share price is 246% less volatile than the S&P 500.
Insider and Institutional Ownership
90.7% of Boston Scientific shares are held by institutional investors. Comparatively, 0.4% of SANUWAVE Health shares are held by institutional investors. 0.7% of Boston Scientific shares are held by company insiders. Comparatively, 23.4% of SANUWAVE Health shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.
Boston Scientific beats SANUWAVE Health on 12 of the 14 factors compared between the two stocks.
About Boston Scientific
Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through three segments: MedSurg, Rhythm and Neuro, and Cardiovascular. The company offers interventional cardiology products, including drug-eluting coronary stent systems used in the treatment of coronary artery disease; percutaneous coronary interventions therapy products to treat atherosclerosis; intravascular catheter-directed ultrasound imaging catheters, fractional flow reserve devices, and systems for use in coronary arteries and heart chambers, as well as certain peripheral vessels; and structural heart therapy systems. It also provides stents, balloon catheters, wires, and atherectomy systems to treat arterial diseases; thrombectomy systems, wires, and stents to treat venous diseases; and peripheral embolization devices, microcatheters, and drainage catheters to treat various cancers. In addition, the company offers cardiac rhythm management devices, such as implantable cardioverter defibrillator systems to treat abnormalities; remote patient management system; implantable cardiac resynchronization therapy pacemaker systems; and medical technologies to diagnose and treat rate and rhythm disorders of the heart comprising ablation catheters, intracardiac ultrasound catheters, diagnostic catheters, delivery sheaths, mapping system, and other accessories. Further, it provides products to diagnose and treat diseases of the gastrointestinal and pulmonary conditions; devices to diagnose, treat, and palliate pulmonary diseases within the airway and lungs; products to treat various urological and pelvic conditions; deep brain stimulation systems for the treatment of parkinson's disease, tremor, and intractable primary and secondary dystonia; and spinal cord stimulator systems for the management of chronic pain. The company was founded in 1979 and is headquartered in Marlborough, Massachusetts.
About SANUWAVE Health
SANUWAVE Health, Inc., a shock wave technology company, focuses on the development and commercialization of noninvasive, high-energy, and acoustic shock waves for regenerative medicine and other applications worldwide. Its shockwaves are used to produce a biological response resulting in the body healing itself through the repair and regeneration of tissue, and musculoskeletal and vascular structures. The company's lead product candidate is the dermaPACE device, which has completed its initial Phase III, IDE clinical trial for treating diabetic foot ulcers. Its portfolio of healthcare products and product candidates activate biologic signaling and angiogenic responses, including new vascularization and microcirculatory improvement, which helps to restore the body's normal healing processes and regeneration. The company also focuses on applying its Pulsed Acoustic Cellular Expression technology in wound healing, orthopedic, plastic/cosmetic, and cardiac conditions. It markets and sells its devices and accessories. SANUWAVE Health, Inc. was founded in 2005 and is headquartered in Suwanee, Georgia.
Receive News & Ratings for Boston Scientific Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Boston Scientific and related companies with MarketBeat.com's FREE daily email newsletter.